
Nagendra K Chaturvedi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/975231/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intracellular localization and nucleocytoplasmic trafficking of steroid receptors: An overview. Molecular and Cellular Endocrinology, 2006, 246, 147-156.	3.2	95
2	Human Prostatic Acid Phosphatase: Structure, Function and Regulation. International Journal of Molecular Sciences, 2013, 14, 10438-10464.	4.1	65
3	Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease. Molecular Medicine, 2014, 20, 290-301.	4.4	59
4	Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e70352.	2.5	39
5	Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Letters, 2011, 311, 177-186.	7.2	35
6	Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. Oncotarget, 2018, 9, 16619-16633.	1.8	35
7	Lymph nodeâ€induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolinâ€1. British Journal of Haematology, 2012, 158, 216-231.	2.5	34
8	Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-ήB and mTOR Dual-Targeting Approach. Molecular Cancer Therapeutics, 2013, 12, 2006-2017.	4.1	27
9	Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood, 2016, 127, 2310-2321.	1.4	23
10	Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. BMC Cancer, 2019, 19, 1056.	2.6	22
11	Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan. Oncotarget, 2016, 7, 15215-15229.	1.8	16
12	Long non-coding RNA profiling of pediatric Medulloblastoma. BMC Medical Genomics, 2020, 13, 87.	1.5	15
13	Suppression of STAT3 NH ₂ â€ŧerminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via deâ€repression by microRNAâ€21. Molecular Carcinogenesis, 2018, 57, 536-548.	2.7	14
14	Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy. Biochemical and Biophysical Research Communications, 2019, 520, 250-256.	2.1	14
15	Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma. Cancers, 2020, 12, 2576.	3.7	12
16	Exosomes secreted under hypoxia enhance stemness in Ewing's sarcoma through miR-210 delivery. Oncotarget, 2020, 11, 3633-3645.	1.8	12
17	A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. Leukemia and Lymphoma, 2019, 60, 1214-1223.	1.3	10
18	A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Molecular Cancer Therapeutics, 2020, 19, 1351-1362.	4.1	10

Nagendra K Chaturvedi

#	Article	IF	CITATIONS
19	Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment. Diagnostics, 2022, 12, 61.	2.6	10
20	Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy. Cancer Letters, 2021, 499, 24-38.	7.2	9
21	Retention and transmission of active transcription memory from progenitor to progeny cells via ligandâ€modulated transcription factors: elucidation of a concept by BIOPIT model. Cell Biology International, 2012, 36, 177-182.	3.0	8
22	Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites. Leukemia and Lymphoma, 2012, 53, 2269-2278.	1.3	7
23	Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. BMC Cancer, 2021, 21, 1061.	2.6	6
24	Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Targeting NF-κB and mTOR Signaling Pathways in Vitro and in Vivo. Blood, 2012, 120, 63-63.	1.4	4
25	Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. Leukemia and Lymphoma, 2016, 57, 2874-2889.	1.3	2
26	Stromal Tumor Microenvironment in CLL: Regulation of Leukemic Progression. Blood, 2012, 120, 1781-1781.	1.4	0
27	The Role Of PRDM1 and Its Interacting Proteins In The Pathogenesis Of Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2865-2865.	1.4	0